FOXO4-DRI is among the highest-risk research peptides from an evidence-to-risk standpoint: it has never been tested in humans, no human pharmacokinetic data exists, and as a senolytic it carries theoretical risks specific to its mechanism
In studies of GLP-1RA therapy in individuals with type 2 diabetes, the most frequently reported adverse events tend to involve the gastrointestinal system, with nausea, vomiting, and diarrhea occurring in up to 51%, 19%, and 20% of patients, respectively [44]
Brain-derived neurotrophic factor levels in the hippocampus increased by ~40% in the 5 mg/kg group
In the AHK-Cu vs GHK-Cu debate, GHK-Cu has the larger body of research behind its potential benefits, while AHK-Cu's research is more specifically focused on hair applications